> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hansoh files China's first domestic TYK2 inhibitor NDA as four local Phase 3 rivals converge
- URL: https://chinapharmadesk.com/hansoh-socrodeucitinib-hs10374-china-tyk2-nda/
- Published: 2026-11-21T11:20:05.000Z
- Updated: 2026-11-21T11:20:06.000Z
- Description: Hansoh Pharmaceutical (HKEX: 03692) won NMPA NDA acceptance on Nov 20, 2026 for TYK2 inhibitor socrodeucitinib (HS-10374, CXHS2600155/156) in plaque psoriasis 60 days after its Phase 3 readout.
- Author: Lin Yi
- Tags: Desk brief, Pipeline, Autoimmune & Immunology, Regulation

[Hansoh Pharmaceutical Group (HKEX: 03692)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1120/2026112001115.pdf?ref=chinapharmadesk.com) disclosed on November 20, 2026 that China’s National Medical Products Administration (`NMPA`) accepted the New Drug Application (`NDA`) for its self-developed oral selective tyrosine kinase 2 (`TYK2`) allosteric inhibitor `socrodeucitinib` (`HS-10374`, [Center for Drug Evaluation (CDE)](https://chinapharmadesk.com/china-pharma-glossary/) acceptance numbers `CXHS2600155` and `CXHS2600156`) for adult patients with moderate-to-severe plaque psoriasis. While four Chinese-originated `TYK2` inhibitors reported positive Phase 3 psoriasis readouts during 2026, Hansoh converted its September 21 Phase 3 top-line readout into a formal `NDA` acceptance in exactly **60 calendar days**—overtaking [InnoCare Pharma (HKEX: 09969; SSE: 688428)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1120/2026112001048.htm?ref=chinapharmadesk.com), which announced positive Phase 3 data for `fadeucravacitinib` (`ICP-488`) two months earlier in July 2026, and securing the first domestic `NDA` slot behind Bristol Myers Squibb’s (`NYSE: BMY`) marketed `Sotyktu` (`deucravacitinib`).

The filing extends Hansoh’s rapid build-out in oral autoimmune dermatology just nine days after its [RMB 317 million AI-driven oral macrocyclic peptide discovery collaboration with AilsynBio](https://chinapharmadesk.com/hansoh-ailsynbio-ai-oral-cyclic-peptide-deal/), while setting up a direct commercial versus clinical-efficacy clash against InventisBio’s (`SSE: 688382`) `nomelcitinib` (`D-2570`), which reported **`>70%` Week 16 `PASI 90` clearance** on November 2.

## Speed to filing versus numerical PASI 90 clearance across six TYK2 programs

Selective `TYK2` inhibitors bind the regulatory pseudokinase (`JH2`) domain rather than the catalytic (`JH1`) domain conserved across `JAK1`, `JAK2`, and `JAK3`, blocking `IL-23`, `IL-12`, and Type I interferon signaling without triggering the lipid, hematologic, and cardiovascular boxed warnings attached to pan-`JAK` inhibitors. However, BMS’s first-in-class `Sotyktu` (`6 mg QD`, approved in China in October 2023 and already listed on the [National Reimbursement Drug List (NRDL)](https://chinapharmadesk.com/china-pharma-glossary/)) left a wide efficacy gap between oral therapy (Week 16 `PASI 90` of \~35.5% and `PASI 100` of \~14.2% in `POETYK PSO-1`) and injectable `IL-17`/`IL-23` biologics.

Next-generation global and Chinese `JH2` allosteric inhibitors were engineered to close that clearance gap by increasing `TYK2` residence time and exposure:

| Drug & Codes                    | Originator / Partner (Ticker)                                                                            | Phase 3 Psoriasis Efficacy (Week 16 unless noted)                                                                                              | Key Phase 2 Reference Data (Week 12)                                                       | Regulatory Status (as of Nov 21, 2026)                                                                  |
| ------------------------------- | -------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------- |
| **socrodeucitinib (HS-10374)**  | **Hansoh Pharma (03692.HK)** (wholly owned)                                                              | **Met co-primary PASI 75 & sPGA 0/1**; **PASI 90 >50%**, **PASI 100 \~33%** (Sept 21, 2026 readout)                                            | NCT06077331 (12 mg QD): PASI 75 72.1%, PASI 90 46.5% vs. 0% placebo                        | **China NMPA NDA accepted Nov 20, 2026 (CXHS2600155 / CXHS2600156) — 1st domestic TYK2 NDA**            |
| **nomelcitinib (D-2570)**       | **InventisBio (688382.SS)** (wholly owned)                                                               | **Met co-primaries (n=391, 1:1:1)**; **PASI 90 >70%** and **PGA 0/1 >80%** across both active dose arms (Nov 2, 2026 readout)                  | NCT06278350 (3 QD doses): PASI 75 85.0%–90.0%, PASI 90 70.7%–77.5%, PASI 100 39.0%–50.0%   | China NDA preparation underway; **running separate China Phase 3 head-to-head vs. Sotyktu** \+ U.S. Ph2 |
| **fadeucravacitinib (ICP-488)** | **InnoCare Pharma (09969.HK / 688428.SS)** (wholly owned)                                                | **Met co-primary PASI 75 & sPGA 0/1** (July 2026 readout; exact Phase 3 PASI 90 % undisclosed)                                                 | NCT06109818 (n=129, 9 mg QD): PASI 75 78.6%, PASI 90 50.0%, PASI 100 11.9%, sPGA 0/1 71.4% | China NDA submission pending (overtaken by Hansoh despite 2-month earlier Ph3 readout)                  |
| **envudeucitinib (ESK-001)**    | **Haisco (002653.SZ) / Alumis (NASDAQ: ALMS)** ($60m upfront + $120m milestones; Kaken Japan $180m deal) | **ONWARD1 & ONWARD2 (Mar 2026)**: Week 16 PASI 90 **59.9% & 53.1%** (Week 24: 68.0% & 62.1%; ONWARD3 Week 48 n=773: PASI 90 75%, PASI 100 54%) | STRIDE (NCT05600036, 40 mg BID): PASI 75 64.1%, PASI 90 38.5%, PASI 100 15.4%              | U.S. FDA NDA submission targeted for **Q4 2026**                                                        |
| **zasocitinib (TAK-279)**       | **Nimbus / Takeda (4502.T / TAK, $4.0b upfront)**                                                        | **LATITUDE Ph3 & LATITUDE Atlas (n=606, June 2026)**: Superior to Sotyktu head-to-head; **PASI 100 >35%** vs. <14% at Week 16                  | NCT04999839 (30 mg QD): PASI 75 67%, PASI 90 46%, PASI 100 33%                             | **U.S. FDA NDA submitted Sept 2026** (decision expected 2027); China Ph3 ongoing                        |
| **deucravacitinib (Sotyktu)**   | **Bristol Myers Squibb (NYSE: BMY)**                                                                     | **POETYK PSO-1 (6 mg QD)**: Week 16 PASI 75 58.4%, PASI 90 35.5%, PASI 100 14.2%                                                               | First-in-class deuterated JH2 reference benchmark                                          | **Approved** (U.S. Sept 2022; China Oct 2023; included on China NRDL)                                   |

## Why Hansoh’s 60-day regulatory sprint matters

Across the domestic cohort, clinical differentiation splits sharply between **execution speed** and **peak skin clearance**. By pushing `socrodeucitinib` (`HS-10374`) from top-line data (September 21) to `NMPA` `NDA` acceptance (November 20) in two months, Hansoh positioned itself for potential China marketing approval in **H1 2028**—establishing a first-mover commercial window among domestic `TYK2` entrants and lining up for the 2028 `NRDL` negotiation cycle. Its Week 16 profile (`>50% PASI 90` and `~33% PASI 100`) roughly doubles `Sotyktu`’s complete-clearance rate and matches Takeda’s `zasocitinib` (`TAK-279`).

However, Hansoh will not hold an uncontested efficacy lead for long. InventisBio’s `nomelcitinib` (`D-2570`) posted **`>70%` Week 16 `PASI 90`** across 391 Phase 3 patients on November 2—matching injectable anti-`IL-17`/`IL-23` biologics and [Haisco’s (002653.SZ) newly registered oral IL-23 inhibitor HSK47388](https://chinapharmadesk.com/haisco-hsk47388-oral-il23-phase3/)—and is already running a dedicated head-to-head China Phase 3 trial against `Sotyktu`.

## Next evidence triggers to watch

- **`CDE` `NDA` acceptance numbers for `ICP-488` and `D-2570` (Q4 2026 – Q1 2027)**: Whether InnoCare (`09969.HK`) and InventisBio (`688382.SS`) file their China `NDAs` before year-end 2026, determining how many months of domestic commercial exclusivity `HS-10374` captures.
- **Full Phase 3 dataset disclosures at 2027 dermatology congresses (`AAD 2027` / `EADV`)**: Complete dose-by-dose `PASI 75/90/100` tables, `CPK` elevation, acne/folliculitis, and herpes zoster rates for `HS-10374` versus `D-2570` and `ICP-488`, alongside any ex-China out-licensing transaction for `D-2570` or `HS-10374`.